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Abstract
Introduction: The aim of our study was to investigate the presence of disease activity in the metatarsophalangeal 
(MTP) joints of the forefoot in rheumatoid arthritis (RA) patients in remission according to the Disease Activity Score 
based on 28 joints (DAS28) remission criterion.
Methods: A total of 848 patients with recent-onset RA were included from 1995 through 2007. The DAS28 and pain 
and swelling of the MTP joints were assessed annually. The data were analyzed using descriptive techniques.
Results: On average, 35% of the patients fulfilled the remission criterion of DAS28 <2.6 during the first eight years of 
RA. On average, 29% of these patients had at least one painful MTP joint and, on average, 31% had at least one swollen 
MTP joint during follow-up. Forty percent, on average, had at least one involved MTP joint (pain and/or swelling).
Conclusions: Painful and/or swollen MTP joints were detected in a substantial proportion of patients classified as 
being in remission. Therefore, examination of the foot joints - irrespective of the patient's state of remission - seems 
indicated in order to provide optimal foot care.
Introduction
Forefoot disease activity appears to be frequent in rheuma-
toid arthritis (RA). In a cohort of patients with recent-onset
RA and a maximum of eight years follow up, prevalence
rates for pain and swelling of the metatarsophalangeal
(MTP) joints were initially high and then stabilized at
around 40% during the eight-year course of RA [1]. Fore-
foot disease activity can lead to joint damage, pain and dis-
ability in weight bearing activities.
The medical treatment policy is often based on the dis-
ease activity score with a 28 joint count (DAS28)[2]. The
feet are omitted in this score, as they are less easily accessi-
ble for clinical examination in daily practice than the hands.
The DAS28 can be used to define clinical remission of the
disease. Values of the DAS28 below 2.6 are reported to cor-
respond with being in clinical remission [3]. Whether fore-
foot disease activity is present in patients who are in
remission according to the DAS28 is unknown. Therefore,
the aim of the present study is to investigate forefoot dis-
ease activity in RA patients in remission.
Materials and methods
Study design
Since 1995, patients age >18 years with recent-onset arthri-
tis (peripheral arthritis of >2 joints and symptom duration
less than three years) have been included in the early arthri-
tis cohort (EAC) [4]of the Jan van Breemen Institute (a
large rheumatology clinic in Amsterdam, The Netherlands).
In the EAC, the patients' disease activity, joint damage, and
functional capacity have been assessed at different time
points. The local ethics committee (Slotervaart Hospital
and Jan van Breemen Institute, Amsterdam, The Nether-
lands) approved the study protocol. All patients gave writ-
ten informed consent to be included in the study. Drug
treatment decisions were made by the rheumatologists
according to clinical practice standards.
For the present study, all patients included between 1995
and May 2007 and fulfilling the 1987 American College of
Rheumatology (ACR; formerly the American Rheumatism
Association) criteria for RA [5] at baseline and/or at one
year after inclusion were selected. Data from annual assess-
ments were used, with a maximum of eight years of follow
up.
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Disease activity
Global disease activity with a 28-joint count (DAS28) was
determined at every annual measurement point [2]. Beside
the 28-joint count, pain and swelling of the MTP joints
were assessed annually. The DAS28 and the number of
painful and/or swollen MTP joints per measurement point
were used for the analysis.
Baseline patient characteristics
Demographic data, duration of symptoms, IgM rheumatoid
factor (RF), joint damage of the hands and feet scored with
the Sharp/van der Heijde method (in a subgroup of patients
with a follow up ≥ 2 years), and functional capacity mea-
sured with the Health Assessment Questionnaire (HAQ)
were recorded at baseline.
Statistical analysis
Means and medians were calculated for the characteristics
of the patients at baseline. Additionally, the percentage of
patients in remission (DAS28 <2.6) was calculated at every
annual measurement point from baseline to a maximum of
eight years of follow up. From these patients in remission
the percentage of patients who had 0, 1, 2 to 4 or 5 to 10
painful and/or swollen MTP joints was calculated for each
year of follow up and visualised in graphs.
All analyses were performed using SPSS, version 15.0
(SPSS, Chicago, IL).
Results
A total of 848 (52%) patients fulfilled the ACR criteria for
RA within the first year and were included in our study.
These 848 patients had at least a baseline measurement.
The duration of follow-up varied between patients, as
patients have been included from 1995 through May 2007.
A total of 682 patients had a follow-up of one year, 341
patients had a follow-up of four years and 121 patients had
a full follow-up of eight years. In our earlier report on the
same cohort, we have analyzed the drop-out from the
cohort. The most common reasons for patients to drop out
were no time (n = 81), moving to another area (n = 46), and
remission of the disease (n = 37). Selection bias was con-
cluded to be minimal as a result of drop-out [1].
The baseline characteristics of the patients are shown in
Table 1.
On average, 35% (range 28% to 40%) of the patients ful-
filled the remission criterion of DAS28 <2.6 during follow-
up (that is, from Year 1 to Year 8; at baseline only 2% of the
patients were in remission). Figure 1 shows which percent-
age of the patients in remission had 0, 1, 2 to 4, and 5 to 10
painful (Figure 1a) and swollen MTP (Figure 1b) joints per
measurement point. On average, 29% of these patients had
at least one painful MTP joint. On average, 31% had at least
one swollen MTP joint during follow-up. Forty percent, on
average, had at least one involved MTP joint (pain and/or
swelling). The percentage of patients in remission with at
least five involved MTP joints was on average 7% and 9%
for pain and swelling, respectively.
Discussion
The results of the present study showed that a substantial
proportion of RA patients, considered to be in remission
according to the DAS28 criterion, had disease activity in
the forefoot joints. About 40% of the patients in remission
had at least one painful and/or swollen MTP joint during
the first eight years of RA. This suggests that the DAS28
remission criterion for RA neglects patients with active
forefoot involvement.
The DAS28 cut-off point for remission of 2.6 has been
discussed in several studies. The original DAS, including a
44-joint count, has a cut-off point of 1.6 for remission [6].
Landewé et al (2006) found that the DAS remission crite-
Table 1: Patient characteristics at baseline (N = 848)
Characteristic Value
Female, % 69
Age, mean (SD) years 55.2 (14.2)
Duration of symptoms, median (IQR) 0.0 (0.0 to 1.0)
Rheumatoid factor positive, % 51.3
DAS28, mean (SD) 5.2 (1.2)
SHS total, median (IQR)/mean (SD) 0.0 (0.0 to 3.0)/4.1(12.2)
HAQ DI total score, median (IQR) 1.1 (0.6 to 1.9)
DAS28 = Disease Activity Score in 28 joints; HAQ DI = Health Assessment Questionnaire disability index; IQR = Interquartile range; SHS total = total Sharp/
van der Heijde score for a subgroup of patients with a follow up ≥ 2 years;
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DAS28 remission criterion [7]. This discrepancy can be
accounted for by the assessment of disease activity in
joints, such as ankles and feet that are excluded from the
DAS28. The study concluded that the DAS28 cut-off point
of 2.6 for RA remission has insufficient construct validity
and should therefore be used with caution in clinical prac-
tice and trials. Mäkinen et al (2005) found that a substantial
proportion of patients, who had a DAS28 score below the
2.6 cut-off point, had tender and/or swollen joints and
therefore concluded that the DAS28 may not be an appro-
priate tool for assessment of remission in RA [8]. However,
Kapral et al (2007) compared a 28-joint count with a 32-
joint count (including ankles and MTP joints) in composite
indices and concluded that reduced joint counts (without
ankles and MTP joints) in composite indices are appropri-
ate and valid tools for disease activity assessment [9]. Fur-
thermore, a study of van der Heijde et al (2005) showed no
differences between the DAS44 and DAS28 in assessing
remission [10]. As a consequence of these findings and
given that the DAS28 is easier to use than the original DAS,
the DAS28 remission criterion remains frequently used to
assess remission in clinical practice and clinical trials.
Our results showed that a substantial proportion of
patients classified as being in remission according to the
DAS28 criterion had disease activity in the MTP joints.
Because undetected disease activity can result in non opti-
mal foot care, we recommend examining the foot joints
when using the DAS28 remission criterion in clinical prac-
tice. Optimal foot care for patients with RA can be achieved
using both medical and conservative modalities.
A limitation of our study is that we report on data of dis-
ease activity in MTP joints only. Although MTP joints are
most commonly affected in RA, further research should
include disease activity in other foot joints beside the MTP
joints.
In our earlier report on the same cohort, we investigated
the eight-year course of joint damage in the MTP joints in
RA patients. It was shown that the forefoot erosion score
was ≥ 1 in 19% of the patients at baseline, and the preva-
lence of forefoot erosion increased to approximately 60%
after eight years, during which the mean forefoot erosion
score increased from 1.3 to 7.9 [1]. The present study
focuses on disease activity in MTP joints, rather than on
joint damage. A suggestion for future research is to evalu-
ate joint damage in the feet of patients with persistent
remission according to the DAS28.
Conclusions
Of the patients in remission, 40%, on average, had disease
activity (pain and/or swelling) in at least one MTP joint
during the first eight years of RA. On average 29% of these
patients had at least one painful MTP joint, and on average
31% had at least one swollen MTP joint during follow-up.
Given that painful and/or swollen MTP joints were
detected in patients classified as being in remission accord-
ing to the DAS28, examination of the foot joints - irrespec-
tive of the patient's state of remission - seems indicated in
order to provide optimal foot care.
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